Ob/Gyn Medical News about Breast

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Economic Value of Primary Prophylaxis Using Pegfilgrastim Compared with Filgrastim in Patients with Breast Cancer in the UK
Applied Health Economics and Health Policy, 10/20/09

Liu Z et al. – In the UK analysis, pegfilgrastim appears to dominate 11–day use of filgrastim. The value of pegfilgrastim versus 6–day filgrastim at £4161–8526/QALY was very favourable compared with the commonly used threshold in the UK. In this setting, primary prophylaxis with pegfilgrastim may be cost effective compared with filgrastim.

<< Previous
Egg freezing, procreative liberty, and ICSI: the double standards...

Next >>
Activating T regulatory cells for tolerance in early pregnancy —...